Clinical Study

Monoamine Oxidase A and B Gene Polymorphisms and Negative and Positive Symptoms in Schizophrenia

Beatriz Camarena,[1,2] Ana Fresán,[3] Alejandro Aguilar,[2] Raúl Escamilla,[4] Ricardo Saracco,[4] Jorge Palacios,[4] Alfonso Tovilla,[5] and Humberto Nicolini[1,6]

[1] *Posgrado de Ciencias Genómicas, Universidad Autónoma de la Ciudad de México, 03100 México, DF, Mexico*
[2] *Departmento de Genética Psiquiátrica, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, 14370 México, DF, Mexico*
[3] *Subdirección Investigaciones Clínicas, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, 14370 México, DF, Mexico*
[4] *Clínica de Genética Psiquiátrica, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, 14370 México, DF, Mexico*
[5] *División Académica Multidisciplinaria de Comalcalco, Universidad Juárez Autónoma de Tabasco, 86040 Comalcalco, Tabasco, Mexico*
[6] *Servicios de Atención Psiquiátrica, Secretaría de Salud y Grupo Médico Carracci, Carracci 107, 03740 México, DF, Mexico*

Correspondence should be addressed to Humberto Nicolini, nicolini_humberto@yahoo.com

Given that schizophrenia is a heterogeneous disorder, the analysis of clinical characteristics could help to identify homogeneous phenotypes that may be of relevance in genetic studies. Linkage and association studies have suggested that a locus predisposing to schizophrenia may reside within Xp11. We analyzed uVNTR and rs1137070, polymorphisms from *MAOA* and rs1799836 of *MAOB* genes to perform single SNP case-control association study in a sample of 344 schizophrenia patients and 124 control subjects. Single polymorphism analysis of uVNTR, rs1137070 and rs1799836 SNPs did not show statistical differences between cases and controls. Multivariate ANOVA analysis of clinical characteristics showed statistical differences between *MAOB*/rs1799836 and affective flattening scores ($F = 4.852$, $P = 0.009$), and significant association between *MAOA*/uVNTR and affective flattening in female schizophrenia patients ($F = 4.236$, $P = 0.016$) after Bonferroni's correction. Our preliminary findings could suggest that severity of affective flattening may be associated by modifier variants of *MAOA* and *MAOB* genes in female Mexican patients with schizophrenia. However, further large-scale studies using quantitative symptom-based phenotypes and several candidate variants should be analyzed to obtain a final conclusion.

1. Introduction

Schizophrenia is a severe and chronic mental illness with a complex clinical presentation suggesting an etiologic and genetic heterogeneity that could benefit from the definition of particular phenotypes using quantitative heritable components [1].

A recent dopamine hypothesis of schizophrenia suggests a final common pathway of presynaptic striatal hyperdopaminergia caused by an interaction between multiple environmental and genetic risk factors affecting brain function that underlie negative and cognitive symptoms [2]. Negative symptoms such as affective flattening, apathy, and poverty of speech are conceptualized as deficits in normal behaviour.

Positive symptoms are characterized by hallucinations, delusions, and severe thought disorganization.

Family, twin, and adoption studies have provided evidence for genetic influences on pronounced negative symptoms in patients with a family history of schizophrenia, as well as for an association with a particular familial form of the illness [3–5].

Linkage and association studies have suggested that a locus predisposing to schizophrenia may reside within Xp11 [6–8]. However, a meta-analysis study did not confirm association between Xp11 locus and schizophrenia [9]. Based on chromosomal position and participation in catabolism of dopamine pathway, monoamine oxidase (MAO) genes have been proposed as candidate genes in the pathogenesis of

schizophrenia. *MAOA* and *MAOB* genes are oriented tail to tail on the Xp11.23 chromosomal region; both genes comprise 15 homologous exons [10]. A functional polymorphism located on the promoter region of the *MAOA* gene (uVNTR) has been described and characterized by a variable-number tandem repeat (VNTR) of 30 bp sequence that expressing five alleles of 2, 3, 3.5, 4, and 5 copies [11]. Previous association analysis of this polymorphism has been studied with aggressive behaviour in schizophrenia patients [12, 13]. Also, a nonfunctional polymorphism located on exon 14 of the *MAOA* gene has been reported in relation to enzyme activity levels. It is characterized by a C for T substitution in position 1460 (C1460T) that results in an *EcoRV* restriction length polymorphism site (rs1137070) [14]. A meta-analysis study provided no evidence for an association between *MAOA* gene polymorphisms and schizophrenia [15]. However, it was reported a high frequency of a particular *MAOA* haplotype in males with schizophrenia compared with a control group [16]. Moreover, a recently study did not show association between T941G and uVNTR polymorphisms of *MAOA* and schizophrenia [17].

On other hand, low platelet MAO-B activity has been detected in schizophrenia patients [7, 18]. Interestingly, it has been published that selegiline, a selective monoamine oxidase B inhibitor in combination with antipsychotics could be helpful for treating negative symptoms in schizophrenia [19].

MAOB gene contains an A644G polymorphism (rs1799836) located on intron 13 that has been associated with enzyme activity in human brain [20]. On the other hand, haplotype analysis of uVNTR of *MAOA* and A644G polymorphism of *MAOB* has shown that individuals carrying the 3G haplotype have significantly lower MAOA activity levels in their brains [20].

Several studies suggest that *MAOB* gene may be implicated in the susceptibility to schizophrenia [6, 8, 21]. Moreover, a recent study found an association between a *MAOB* microsatellite polymorphism and particular clinical features [22].

The role of MAO genes in the susceptibility to schizophrenia requires further research; therefore, we analyzed *MAOA* and *MAOB* gene polymorphisms to perform single SNP association study in Mexican patients with schizophrenia.

2. Material and Methods

2.1. Sample. The total sample comprised 344 schizophrenia patients (135 females and 209 males), 267 patients from the Instituto Nacional de Psiquiatría Ramón de la Fuente (INPRF), and a sample of 77 patients from Grupo Medico Carracci selected from a study of first psychotic episode. All patients fulfilled DSM-IVR diagnostic criteria for schizophrenia and were based on a structured interview DIGS (Diagnostic Interview for Genetics Studies) Spanish version. Exclusion criteria included concomitant medical or neurological illness, current substance abuse, history of substance dependence, or history of bipolar disorder. Symptom severity was assessed before pharmacological treatment

Table 1: Allele frequencies of *MAOA* and *MAOB* polymorphisms in schizophrenia and control subjects.

	Schizophrenia $n = 344$		Controls $n = 124$	
uVNTR	1	3	1	3
Males	76 (0.36)	133 (0.64)	19 (0.35)	36 (0.65)
Females	112 (0.41)	158 (0.59)	44 (0.40)	66 (0.60)
rs1137070	C	T	C	T
Males	121 (0.58)	88 (0.42)	39 (0.65)	21 (0.35)
Females	143 (0.53)	127 (0.47)	84 (0.66)	44 (0.34)
rs1799836	A	G	A	G
Males	136 (0.65)	73 (0.35)	31 (0.55)	25 (0.45)
Females	185 (0.69)	85 (0.31)	77 (0.58)	55 (0.42)

Schizophrenia: Males = 209.
Females = 135.
Controls: Males = 60.
Females = 64.

with the Scale of the Assessment of Negative Symptoms (SANS) [23] and the Scale of the Assessment of Positive Symptoms (SAPS) [24]. All relevant diagnostic information for each subject was reviewed, blind to marker genotypes, independently by H. Nicolini, A. Fresán, R. Escamilla and R. Saracco.

The control group comprised 124 healthy Mexican subjects (64 females and 60 males), without current or past psychiatric history screened-out by the DIS-Spanish version.

All subjects were from a family background of three generations born in Mexico in order to have a more homogenous sample, because there is known genetic heterogeneity in Latin American and Mexican populations [25]. The study received approval by the appropriate Institutional Review Boards of the INPRF and subjects provided written informed consent.

2.2. Genotyping Analysis of MAOA and MAOB Polymorphisms. Genomic DNA of the subjects was extracted by a standard procedure. The *MAOA*/uVNTR analysis was performed using the primers and conditions described by Sabol et al. [11]. *MAOA* genotyping was performed in 3% MetaPhor gels and visualized under UV light after staining with ethidium bromide. Analysis of the rs1137070, of the *MAOA* gene was performed using the primers and conditions reported by Hotamisligil and Breakefield [14]. PCR products were resolved on 3% agarose gels and visualized under UV illumination after ethidium bromide staining. The rs1799836 of *MAOB* gene was detected using the method described by Matsumoto et al. [26].

2.3. Statistical Analysis. Analysis was performed with the Statistical Package for the Social Science (SPSS) for Windows, version 18.0 (SPSS Inc., Chicago). A Multivariate General Linear Model (Multivariate Analysis of the Variance, MANOVA) was performed to identify differences between the quantitative variables of interest (SANS and SAPS subs-scales) between genotypes. Bonferroni's correction for

TABLE 2: Effect of *MAOA* and *MAOB* genotypes on SANS subscale scores in 135 females with schizophrenia using multivariate ANOVA analysis.

SANS sub-scales	Female genotypes			F	P
MAOA/uVNTR	11	13	33		
Affective flattening	$1.75 \pm 1.1^{*}$	1.96 ± 1.2	2.47 ± 1.1	4.24	**0.016**
Alogia	1.39 ± 1.5	1.58 ± 1.2	2.06 ± 1.2	3.08	0.049
Avolition	2.04 ± 1.3	2.16 ± 1.2	2.35 ± 1.3	0.64	0.528
Anhedonia	2.07 ± 1.3	2.07 ± 1.2	2.63 ± 1.3	3.08	0.049
Attention impairment	1.54 ± 1.3	1.56 ± 1.2	1.96 ± 1.3	1.60	0.206
SANS total	8.79 ± 5.4	9.33 ± 5.2	11.47 ± 5.1	3.26	0.042
MAOB/rs1799836	AA	AG	GG		
Affective flattening	2.13 ± 1.1	1.85 ± 1.1	2.87 ± 1.4	4.85	**0.009**
Alogia	1.75 ± 1.3	1.55 ± 1.2	2.19 ± 1.2	1.55	0.217
Avolition	2.25 ± 1.2	1.96 ± 1.2	2.81 ± 1.4	2.98	0.054
Anhedonia	2.27 ± 1.3	2.11 ± 1.3	2.88 ± 1.3	2.20	0.115
Attention impairment	1.60 ± 1.3	1.75 ± 1.4	2.00 ± 1.1	0.68	0.506
SANS total	10.0 ± 5.2	9.23 ± 5.2	12.75 ± 5.5	2.79	0.065

* Data are presented as Mean $\pm$ SD.
Bonferroni's correction adjusted to $P \leq 0.016$.

multiple testing was applied (3 MAO gene polymorphisms corrected at $P \leq 0.016$).

3. Results

The mean age of the 344 schizophrenia subjects was 32.6 ± 9.8 years (mean $\pm$ s.d.). The age for the onset of illness was 22.1 ± 7.1 years. The mean of SANS total scores was 10.1 ± 5.1 and for SAPS total scores was 5.6 ± 4.4.

We analyzed uVNTR and rs1137070 polymorphisms on the *MAOA* gene and rs1799836 located on the *MAOB* gene. The distribution of *MAOA* and *MAOB* genotypes for schizophrenia and control groups were in Hardy-Weinberg equilibrium ($P > 0.05$).

Allele frequencies of *MAOA* and *MAOB* polymorphisms are shown in Table 1. Two alleles containing 3 and 4 repeats (allele 1 and 3, respectively). for the uVNTR polymorphism were observed in Mexican population (Table 1). Single polymorphism analysis by gender of uVNTR, rs1137070 and rs1799836 SNPs did not show statistical differences between cases and controls (Table 1).

The presence of association of each polymorphism with SANS and SAPS subscale scores were analyzed using Multivariate ANOVA. The comparison between SAPS subscale scores and *MAOA* and *MAOB* gene variants did not show statistical differences (data not shown). However, analysis in female patients of SANS subscale scores showed an effect of genotype on affective flattening score of SANS sub-scale for rs1799836 SNP of *MAOB* gene ($F = 4.852$, $P = 0.009$). Also, a statistical significance was observed between uVNTR polymorphisms of MAOA gene and high scores of affective flattening ($F = 4.236$, $P = 0.016$, Table 2). Therefore, we investigated the existence of a potential dose response of allele 3 of uVNTR and allele G of rs1799836 on the affective flattening scores in female group. MAOA/uVNTR genotype was converted into a quantitative variable that express the number of allele 3 (0 = no 3 allele, 1 = 1 allele 3 and 2 = 2 alleles 3, and MAOB/rs1799836 genotypes was converted in based to number of G alleles (0 = no G allele, 1 = 1 allele G, and 2 = 2 alleles G). Regression analysis was significant only for uVNTR polymorphism ($F = 8.005$, $R^2 = 0.056$, $P = 0.005$).

4. Discussion

Since schizophrenia is a complex disorder characterized by a myriad of symptoms, the use of positive and negative symptom scores as quantitative traits may increase the power to detect association with candidate genes that could be important to define a molecular classification of schizophrenia subtypes.

Genetic studies have reported association between polymorphic variants of DRD2, DRD4, BDNF, MTHFR, and COMT genes and negative symptoms [27–30]. Moreover, significant relationship have been reported between DISC1 gene and the severity of delusions [31, 32], and positive symptoms and allele variants of DRD4 and SLC6A4 [33, 34].

Linkage studies have suggested a probable locus predisposing to schizophrenia within Xp11 [6, 7]. Interestingly, there are two candidate genes within this particular chromosomal region, *MAOA* and *MAOB*.

Our *MAOA* single polymorphism analysis did not show significant association with schizophrenia in agreement with previous studies [17, 35–37]. However, the present study found a trend for significance between the number of 3 alleles of uVNTR of MAOA gene and the severity of affective flattening demonstrated that an effect of dose could be related with *MAOA* gene variants. Our findings are consistent

with previous studies showing an effect dose of gene variants of enzymes that participate in the metabolism of neurotransmitters associated with the negative symptoms in schizophrenia [28].

A differential metabolism of MAO-A and MAO-B enzymes in dopamine metabolism has been reported in several human brain regions. Analysis of platelet MAO activity reported association with negative symptoms in male schizophrenic patients [38]. Also, it has been suggested that an increase in the MAO-B/MAO-A ratio in the brain of schizophrenic patients could be associated with negative symptoms in structural abnormalities related to these particular clinical symptoms [39]. We observed that *MAOB/* rs1799836 polymorphism was associated with the severity of affective flattening. In particular, analysis by gender showed a high severity of affective flattening in female carriers of GG genotype. However, we did not find an effect of dose related with the number of G alleles suggesting that GG genotype could be related to this clinical phenotype. The rs1799836 has been associated with the level of enzyme activity [40, 41] and revealed gender differences in Parkinson's disease [42]. Therefore, it could be possible that genetic variation of *MAOB* suggests a gender subtype of schizophrenia.

Our findings showed that MAO gene variants may be involved in pathways contributing to a schizophrenia symptom severity. Interestingly, affective flattening and alogia are independent of medication status and persist for many years [43, 44]. Therefore, our results provide support for the hypothesis that polymorphic regions influence clinical features once the disease is present.

It was reported a haplotype analysis of uVNTR of *MAOA* and A644G polymorphism of *MAOB* showing that individuals carrying the 3G haplotype have significantly lower MAOA activity levels in their brains [45]. We observed weak LD between the regions analyzed, suggesting that haplotypes had been broken up by recombination. Interestingly, *MAOA* and *MAOB* have been reported as candidate loci subject to a recent positive selection [21].

Limitations of the present study were the small sample size, the number of MAO genetic variants analyzed, and the clinical heterogeneity of the schizophrenia patients.

In conclusion, our preliminary findings could indicate that the severity of negative symptoms might be associated by modifier variants of *MAOA* and *MAOB* genes in Mexican patients with schizophrenia, in particular, with affective flattening dimension. The complexity of psychiatric disorders requires a multidisciplinary integration of genetics, neuroscience, psychiatry, and molecular biology to obtain a final conclusion. For the moment, to gain further insight into this hypothesis, we suggest that further large-scale studies using quantitative symptom-based phenotypes and several candidate variants should be undertaken to understand the role of *MAO* genes in schizophrenia pathogenesis.

Acknowledgments

References

[1] A. H. Fanous and K. S. Kendler, "Genetic heterogeneity, modifier genes, and quantitative phenotypes in psychiatric illness: searching for a framework," *Molecular Psychiatry*, vol. 10, no. 1, pp. 6–13, 2005.

[2] O. D. Howes and S. Kapur, "The dopamine hypothesis of schizophrenia: version III—The final common pathway," *Schizophrenia Bulletin*, vol. 35, no. 3, pp. 549–562, 2009.

[3] R. Arajarvi, T. Varilo, J. Haukka et al., "Affective flattening and alogia associate with the familial form of schizophrenia," *Psychiatry Research*, vol. 141, no. 2, pp. 161–172, 2006.

[4] A. G. Cardno, K. Thomas, and P. McGuffin, "Clinical variables and genetic loading for schizophrenia: analysis of published Danish adoption study data," *Schizophrenia Bulletin*, vol. 28, no. 3, pp. 393–399, 2002.

[5] H. Wickham, C. Walsh, P. Asherson et al., "Familiality of symptom dimensions in schizophrenia," *Schizophrenia Research*, vol. 47, no. 2-3, pp. 223–232, 2001.

[6] J. Dann, L. E. DeLisi, M. Devoto et al., "A linkage study of schizophrenia to markers within Xp11 near the MAOB gene," *Psychiatry Research*, vol. 70, no. 3, pp. 131–143, 1997.

[7] L. E. DeLisi and T. J. Crow, "Evidence for a sex chromosome locus for schizophrenia," *Schizophrenia Bulletin*, vol. 15, no. 3, pp. 431–440, 1989.

[8] J. Wei and G. P. Hemmings, "A study of linkage disequilibrium between polymorphic loci for monamine oxidases A and B in schizophrenia," *Psychiatric Genetics*, vol. 9, no. 4, pp. 177–181, 1999.

[9] M. Y. M. Ng, D. F. Levinson, S. V. Faraone, B. K. Suarez et al., "Meta-analysis of 32 genome-wide linkage studies of schizophrenia," *Molecular Psychiatry*, vol. 14, no. 8, pp. 774–785, 2009.

[10] J. Grimsby, K. Chen, L. J. Wang, N. C. Lan, and J. C. Shih, "Human monoamine oxidase A and B genes exhibit identical exon-intron organization," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 88, no. 9, pp. 3637–3641, 1991.

[11] S. Z. Sabol, S. Hu, and D. Hamer, "A functional polymorphism in the monoamine oxidase A gene promoter," *Human Genetics*, vol. 103, no. 3, pp. 273–279, 1998.

[12] A. Fresan, B. Camarena, R. Apiquian, A. Aguilar, N. Urraca, and H. Nicolini, "Association study of MAO-A and DRD4 genes in schizophrenic patients with aggressive behavior," *Neuropsychobiology*, vol. 55, no. 3-4, pp. 171–175, 2007.

[13] S. Zammit, G. Jones, S. J. Jones et al., "Polymorphisms in the MAOA, MAOB, and COMT genes and aggressive behavior in schizophrenia," *American Journal of Medical Genetics - Neuropsychiatric Genetics*, vol. 128, no. 1, pp. 19–20, 2004.

[14] G. S. Hotamisligil and X. O. Breakefield, "Human monoamine oxidase A gene determines levels of enzyme activity," *American Journal of Human Genetics*, vol. 49, no. 2, pp. 383–392, 1991.

[15] D. Li and L. He, "Meta-study on association between the monoamine oxidase A gene (MAOA) and schizophrenia," *American Journal of Medical Genetics B*, vol. 147, no. 2, pp. 174–178, 2008.

[16] H. T. Qiu, H. Q. Meng, C. Song et al., "Association between monoamine oxidase (MAO)-A gene variants and schizophrenia in a Chinese population," *Brain Research*, vol. 1287, pp. 67–73, 2009.

[17] S. Alvarez, S. Mas, P. Gassó et al., "Lack of association between schizophrenia and polymorphisms in dopamine metabolism and transport genes," *Fundamental and Clinical Pharmacology*, vol. 24, no. 6, pp. 741–747, 2010.

[18] W. H. Berrettini, W. H. Vogel, and R. Clouse, "Platelet monoamine oxidase in chronic schizophrenia," *American Journal of Psychiatry*, vol. 134, no. 7, pp. 805–806, 1977.

[19] A. Amiri, A. A. Noorbala, A. A. Nejatisafa et al., "Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study," *Human Psychopharmacology*, vol. 23, no. 2, pp. 79–86, 2008.

[20] J. Balciuniene, L. Emilsson, L. Oreland, U. Pettersson, and E. E. Jazin, "Investigation of the functional effect of monoamine oxidase polymorphisms in human brain," *Human Genetics*, vol. 110, no. 1, pp. 1–7, 2002.

[21] N. Carrera, J. Sanjuan, M. D. Molto et al., "Recent adaptive selection at MAOB and ancestral susceptibility to schizophrenia," *American Journal of Medical Genetics B*, vol. 5, no. 150, pp. 369–374, 2009.

[22] S. E. Bergen, A. H. Fanous, D. Walsh, and K. S. Kendler, "Polymorphisms in SLC6A4, PAH, GABRB3, and MAOB and modification of psychotic disorder features," *Schizophrenia Research*, vol. 109, no. 1–3, pp. 94–97, 2009.

[23] N. Andreasen, *The Scale for the Assessment of Negative Symptoms (SANS)*, University of Iowa, Iowa City, IA, USA, 1983.

[24] N. Andreasen, *The Scale for the Assessment of Positive Symptoms (SAPS)*, University of Iowa, Iowa City, IA, USA, 1984.

[25] S. Wang, N. Ray, W. Rojas et al., "Geographic patterns of genome admixture in latin American mestizos," *PLoS Genetics*, vol. 4, no. 3, Article ID e1000037, 2008.

[26] C. Matsumoto, T. Shinkai, H. Hori, O. Ohmori, and J. Nakamura, "Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia," *Psychiatry Research*, vol. 127, no. 1-2, pp. 1–7, 2004.

[27] A. Serretti, E. Lattuada, C. Lorenzi, R. Lilli, and E. Smeraldi, "Dopamine receptor D2 Ser/Cys 311 variant is associated with delusion and disorganization symptomatology in major psychoses," *Molecular Psychiatry*, vol. 5, no. 3, pp. 270–274, 2000.

[28] A. H. Fanous, M. C. Neale, R. E. Straub et al., "Clinical features of psychotic disorders and polymorphisms in HT2A, DRD2, DRD4, SLC6A3 (DAT1), and BDNF: a family based sssociation study," *American Journal of Medical Genetics - Neuropsychiatric Genetics*, vol. 125, no. 1, pp. 69–78, 2004.

[29] J. M. Pelayo-Terán, T. Pérez-Iglesias, J. Vázquez-Bourgon et al., "Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis," *Psychiatry Research*, vol. 185, no. 1-2, pp. 286–289, 2011.

[30] J. L. Roffman, A. P. Weiss, S. Purcell et al., "Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia," *Biological Psychiatry*, vol. 63, no. 1, pp. 42–48, 2008.

[31] P. DeRosse, C. A. Hodgkinson, T. Lencz et al., "Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia," *Biological Psychiatry*, vol. 61, no. 10, pp. 1208–1210, 2007.

[32] W. Hennah, T. Varilo, M. Kestila et al., "Haplotype transmission analysis provides evidence of association for DISC1 to schizophrenia and suggests sex-dependent effects," *Human Molecular Genetics*, vol. 12, no. 23, pp. 3151–3159, 2003.

[33] A. K. Malhotra, D. Goldman, C. Mazzanti, A. Clifton, A. Breier, and D. Pickar, "A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics," *Molecular Psychiatry*, vol. 3, no. 4, pp. 328–332, 1998.

[34] A. Serretti, R. Lilli, C. Lorenzi, E. Lattuada, and E. Smeraldi, "DRD4 exon 3 variants associated with delusional symptomatology in major psychoses: a study on 2,011 affected subjects," *American Journal of Medical Genetics - Neuropsychiatric Genetics*, vol. 105, no. 3, pp. 283–290, 2001.

[35] J. B. Fan, M. S. Yang, J. X. Tang et al., "Family-based association study of the functional monoamine oxidase A gene promoter polymorphism and schizophrenia," *Schizophrenia Research*, vol. 67, no. 1, pp. 107–109, 2004.

[36] N. Norton, G. Kirov, S. Zammit et al., "Schizophrenia and functional polymorphisms in the MAOA and COMT genes: no evidence for association or epistasis," *American Journal of Medical Genetics - Neuropsychiatric Genetics*, vol. 114, no. 5, pp. 491–496, 2002.

[37] Y. V. Syagailo, G. Stober, M. Grassle et al., "Association analysis of the functional monoamine oxidase a gene promoter polymorphism in psychiatric disorders," *American Journal of Medical Genetics - Neuropsychiatric Genetics*, vol. 105, no. 2, pp. 168–171, 2001.

[38] R. J. Lewine and H. Y. Meltzer, "Negative symptoms and platelet monoamine oxidase activity in male schizophrenic patients," *Psychiatry Research*, vol. 12, no. 2, pp. 99–109, 1984.

[39] C. J. Fowler, A. Carlsson, and B. Winblad, "Monoamine oxidase-A and -B activities in the brain stem of schizophrenics and non-schizophrenic psychotics," *Journal of Neural Transmission*, vol. 52, no. 1-2, pp. 23–32, 1981.

[40] P. Costa-Mallen, S. N. Kelada, L. G. Costa, and H. Checkoway, "Characterization of the in vitro transcriptional activity of polymorphic alleles of the human monoamine oxidase-B gene," *Neuroscience Letters*, vol. 383, no. 1-2, pp. 171–175, 2005.

[41] H. Garpenstrand, J. Ekblom, K. Forslund, G. Rylander, and L. Oreland, "Platelet monoamine oxidase activity is related to MAOB intron 13 genotype," *Journal of Neural Transmission*, vol. 107, no. 5, pp. 523–530, 2000.

[42] S. N. Kelada, P. Costa-Mallen, L. G. Costa et al., "Gender difference in the interaction of smoking and monoamine oxidase B intron 13 genotype in Parkinson's disease," *Neurotoxicology*, vol. 23, no. 4-5, pp. 515–519, 2002.

[43] E. S. Herbener and M. Harrow, "Longitudinal assessment of negative symptoms in schizophrenia/schizoaffective patients, other psychotic patients, and depressed patients," *Schizophrenia Bulletin*, vol. 27, no. 3, pp. 527–537, 2001.

[44] M. E. Kelley, D. P. Van Kammen, and D. N. Allen, "Empirical validation of primary negative symptoms: independence from effects of medication and psychosis," *American Journal of Psychiatry*, vol. 156, no. 3, pp. 406–411, 1999.

[45] J. Balciuniene, L. Emilsson, L. Oreland, U. Pettersson, and E. E. Jazin, "Investigation of the functional effect of monoamine oxidase polymorphisms in human brain," *Human Genetics*, vol. 110, no. 1, pp. 1–7, 2002.

The Scientific
World Journal

Gastroenterology
Research and Practice

MEDIATORS
of
INFLAMMATION

Journal of
Diabetes Research

Disease Markers

Journal of
Immunology Research

International Journal of
Endocrinology

PPAR Research

BioMed
Research International

Hindawi

Submit your manuscripts at
http://www.hindawi.com

Journal of
Ophthalmology

Stem Cells
International

^{e}CAM

Evidence-Based
Complementary and
Alternative Medicine

Journal of
Obesity

Journal of
Oncology

Computational and
Mathematical Methods
in Medicine

Behavioural
Neurology

Parkinson's
Disease

AIDS
Research and Treatment

Oxidative Medicine and
Cellular Longevity